Thermo Fisher Scientific (TMO) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jul. 02, 2022 shares
Entity Listings [Line Items]
Entity Central Index Key	0000097745
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 02, 2022
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	391,788,962
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
Senior Notes 0.125% Due 2025 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($)	Jul. 02, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,888,000,000	$ 4,477,000,000
Accounts receivable, less allowances of $177 and $150	7,745,000,000	7,977,000,000
Inventories	5,668,000,000	5,051,000,000
Contract assets, net	1,147,000,000	968,000,000
Other current assets	1,652,000,000	1,640,000,000
Total current assets	18,100,000,000	20,113,000,000
Property, plant and equipment, net	8,529,000,000	8,333,000,000
Acquisition-related intangible assets, net	18,578,000,000	20,113,000,000
Other assets	4,306,000,000	4,640,000,000
Goodwill	41,066,000,000	41,924,000,000
Total assets	90,579,000,000	95,123,000,000
Current liabilities:
Short-term obligations and current maturities of long-term obligations	1,010,000,000	2,537,000,000
Accounts payable	2,586,000,000	2,867,000,000
Accrued payroll and employee benefits	1,722,000,000	2,427,000,000
Contract liabilities	2,722,000,000	2,655,000,000
Other accrued expenses	2,957,000,000	2,950,000,000
Total current liabilities	10,997,000,000	13,436,000,000
Deferred income taxes	3,327,000,000	3,837,000,000
Other long-term liabilities	4,534,000,000	4,540,000,000
Long-term obligations	29,250,000,000	32,333,000,000
Redeemable noncontrolling interest	117,000,000	122,000,000
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 439,863,357 and 439,154,741 shares issued	440,000,000	439,000,000
Capital in excess of par value	16,467,000,000	16,174,000,000
Retained earnings	39,074,000,000	35,431,000,000
Treasury stock at cost, 48,074,395 and 44,720,112 shares	(10,964,000,000)	(8,922,000,000)
Accumulated other comprehensive items	(2,724,000,000)	(2,329,000,000)
Total Thermo Fisher Scientific Inc. shareholders’ equity	42,293,000,000	40,793,000,000
Noncontrolling interests	61,000,000	62,000,000
Total equity	42,354,000,000	40,855,000,000
Total liabilities, redeemable noncontrolling interest and equity	$ 90,579,000,000	$ 95,123,000,000

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jul. 02, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 177	$ 150
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	439,863,357	439,154,741
Treasury Stock at Cost (in shares)	48,074,395	44,720,112

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Revenues
Revenues	$ 10,970	$ 9,273	$ 22,788	$ 19,179
Costs and operating expenses:
Selling, general and administrative expenses	2,209	1,899	4,486	3,725
Research and development expenses	365	343	729	663
Restructuring and other costs	24	119	26	133
Total costs and operating expenses	8,969	7,110	17,966	13,967
Operating income	2,001	2,163	4,822	5,212
Interest income	36	11	54	23
Interest expense	(148)	(122)	(284)	(247)
Other income/(expense)	28	(3)	(135)	(186)
Income before income taxes	1,917	2,049	4,457	4,802
Provision for income taxes	(198)	(219)	(499)	(635)
Equity in earnings/(losses) of unconsolidated entities	(51)	(1)	(70)	(1)
Net income	1,668	1,829	3,888	4,166
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest	4	1	9	1
Net income	$ 1,664	$ 1,828	$ 3,879	$ 4,165
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 4.25	$ 4.65	$ 9.90	$ 10.58
Diluted (in dollars per share)	$ 4.22	$ 4.61	$ 9.83	$ 10.50
Weighted average shares
Basic (in shares)	392	393	392	394
Diluted (in shares)	394	396	394	397
Product [Member]
Revenues
Revenues	$ 7,003	$ 7,214	$ 15,020	$ 15,070
Costs and operating expenses:
Cost of revenues	3,516	3,352	7,071	6,679
Service [Member]
Revenues
Revenues	3,967	2,059	7,768	4,109
Costs and operating expenses:
Cost of revenues	$ 2,855	$ 1,397	$ 5,654	$ 2,767

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Comprehensive income
Net income	$ 1,668	$ 1,829	$ 3,888	$ 4,166
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $173, $(23), $262 and $95)	(386)	(71)	(416)	153
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $1, $1 and $5)	0	1	1	14
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $(2), $0, $(3) and $(2))	6	(2)	9	4
Amortization of net loss included in net periodic pension cost (net of tax benefit of $1, $1, $2 and $2)	2	4	4	6
Total other comprehensive items	(378)	(68)	(402)	177
Comprehensive income	1,290	1,761	3,486	4,343
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	7	1	2	1
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$ 1,283	$ 1,760	$ 3,484	$ 4,342

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 173	$ (23)	$ 262	$ 95
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	1	1	1	5
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	(2)	0	(3)	(2)
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 1	$ 1	$ 2	$ 2

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Operating activities
Net income	$ 3,888	$ 4,166
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	486	409
Amortization of acquisition-related intangible assets	1,209	872
Change in deferred income taxes	(601)	(307)
Loss on early extinguishment of debt	26	197
Stock-based compensation	155	102
Other non-cash expenses, net	291	213
Changes in assets and liabilities, excluding the effects of acquisitions	(1,724)	(1,447)
Net cash provided by operating activities	3,730	4,205
Investing activities
Acquisitions, net of cash acquired	(40)	(1,425)
Purchase of property, plant and equipment	(1,146)	(1,168)
Proceeds from sale of property, plant and equipment	14	5
Other investing activities, net	83	(36)
Net cash used in investing activities	(1,089)	(2,624)
Financing activities
Repayment of debt	(375)	(2,803)
Proceeds from issuance of commercial paper	1,032	0
Repayments of commercial paper	(3,490)	0
Purchases of company common stock	(2,000)	(2,000)
Dividends paid	(220)	(190)
Net proceeds from issuance of company common stock under employee stock plans	51	72
Other financing activities, net	(48)	(5)
Net cash used in financing activities	(5,050)	(4,926)
Exchange rate effect on cash	(177)	44
Decrease in cash, cash equivalents and restricted cash	(2,586)	(3,301)
Cash, cash equivalents and restricted cash at beginning of period	4,491	10,336
Cash, cash equivalents and restricted cash at end of period	$ 1,905	$ 7,035

Consolidated Statement of Redee

Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock, $1.00 par value	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]	Total Thermo Fisher Scientific Inc. Shareholders' Equity	Noncontrolling Interest
Balance (in shares) at Dec. 31, 2020		437			40
Balance at Dec. 31, 2020	$ 34,517	$ 437	$ 15,579	$ 28,116	$ (6,818)	$ (2,807)	$ 34,507	$ 10
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1			1
Issuance of shares under employees' and directors' stock plans	108	$ 1	145		$ (38)		108
Stock-based compensation	102		102				102
Purchases of company common stock (in shares)					4
Purchases of company common stock	(2,000)				$ (2,000)		(2,000)
Dividends declared	(205)			(205)			(205)
Net income	4,166			4,165			4,165	1
Total other comprehensive items	177					177	177
Contribution from (distributions to) noncontrolling interests	36							36
Balance (in shares) at Jul. 03, 2021		438			45
Balance at Jul. 03, 2021	36,901	$ 438	15,826	32,076	$ (8,856)	(2,630)	36,854	47
Balance (in shares) at Apr. 03, 2021		438			45
Balance at Apr. 03, 2021	35,068	$ 438	15,684	30,350	$ (8,852)	(2,562)	35,058	10
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)					0
Issuance of shares under employees' and directors' stock plans	87		91		$ (4)		87
Stock-based compensation	51		51				51
Dividends declared	(102)			(102)			(102)
Net income	1,829			1,828			1,828	1
Total other comprehensive items	(68)					(68)	(68)
Contribution from (distributions to) noncontrolling interests	36							36
Balance (in shares) at Jul. 03, 2021		438			45
Balance at Jul. 03, 2021	36,901	$ 438	15,826	32,076	$ (8,856)	(2,630)	36,854	47
Redeemable Noncontrolling Interest, Balance at Dec. 31, 2021	122
Redeemable Noncontrolling Interest [Roll Forward]
Net income (loss) attributable to redeemable noncontrolling interest	9
Other comprehensive items attributable to redeemable noncontrolling interest	(7)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(7)
Redeemable Noncontrolling Interest, Balance at Jul. 02, 2022	117
Balance (in shares) at Dec. 31, 2021		439			45
Balance at Dec. 31, 2021	40,855	$ 439	16,174	35,431	$ (8,922)	(2,329)	40,793	62
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1			0
Issuance of shares under employees' and directors' stock plans	97	$ 1	138		$ (42)		97
Stock-based compensation	155		155				155
Purchases of company common stock (in shares)					3
Purchases of company common stock	(2,000)				$ (2,000)		(2,000)
Dividends declared	(236)			(236)			(236)
Net income	3,879			3,879			3,879
Total other comprehensive items	(395)					(395)	(395)
Contribution from (distributions to) noncontrolling interests	(1)							(1)
Balance (in shares) at Jul. 02, 2022		440			48
Balance at Jul. 02, 2022	42,354	$ 440	16,467	39,074	$ (10,964)	(2,724)	42,293	61
Redeemable Noncontrolling Interest, Balance at Apr. 02, 2022	113
Redeemable Noncontrolling Interest [Roll Forward]
Net income (loss) attributable to redeemable noncontrolling interest	4
Other comprehensive items attributable to redeemable noncontrolling interest	4
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(4)
Redeemable Noncontrolling Interest, Balance at Jul. 02, 2022	117
Balance (in shares) at Apr. 02, 2022		440			48
Balance at Apr. 02, 2022	41,018	$ 440	16,292	37,528	$ (10,961)	(2,343)	40,956	62
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)					0
Issuance of shares under employees' and directors' stock plans	95		98		$ (3)		95
Stock-based compensation	77		77				77
Dividends declared	(118)			(118)			(118)
Net income	1,664			1,664			1,664
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest								(1)
Total other comprehensive items	(382)					(381)	(381)
Balance (in shares) at Jul. 02, 2022		440			48
Balance at Jul. 02, 2022	$ 42,354	$ 440	$ 16,467	$ 39,074	$ (10,964)	$ (2,724)	$ 42,293	$ 61

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.30	$ 0.26	$ 0.60	$ 0.52

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jul. 02, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at July 2, 2022, the results of operations for the three- and six-month periods ended July 2, 2022 and July 3, 2021, and the cash flows for the six-month periods ended July 2, 2022 and July 3, 2021. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet presented as of December 31, 2021, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2021 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Note 1 to the consolidated financial statements for 2021 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the six months ended July 2, 2022. Inventories The components of inventories are as follows: July 2, December 31, (In millions) 2022 2021 Raw materials $ 2,335 $ 1,922 Work in process 699 676 Finished goods 2,634 2,453 Inventories $ 5,668 $ 5,051 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. The negative impacts associated with the ongoing COVID-19 global pandemic significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company will adopt this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of transactions of this nature entered into by the company.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 02, 2022
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. 2022 In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies. 2021 The preliminary allocations of the purchase price for the acquisitions of the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc. were based on estimates of the fair values of the net assets acquired and are subject to adjustment upon finalization, largely with respect to acquired intangible assets, lease assets and liabilities, and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions. During the first six months of 2022, the company adjusted the preliminary allocations of PPD and PeproTech, which among others increased goodwill ($95 million) and other liabilities assumed ($22 million), and decreased definite-lived intangible assets ($43 million), other current assets ($34 million), contract liabilities ($29 million), equity method investments ($23 million), and the fair value of assumed contingent consideration ($18 million). The adjustment to amortization expense recorded during the first six months of 2022 was not material.

Revenue and Contract-related Ba

Revenue and Contract-related Balances	6 Months Ended
	Jul. 02, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenues and Contract-related Balances Disaggregated Revenues Revenues by type are as follows: Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues Consumables $ 4,993 $ 5,372 $ 11,103 $ 11,336 Instruments 2,010 1,842 3,917 3,734 Services 3,967 2,059 7,768 4,109 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179 Revenues by geographic region based on customer location are as follows: Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues North America $ 6,032 $ 4,529 $ 12,355 $ 9,630 Europe 2,551 2,695 5,601 5,480 Asia-Pacific 2,042 1,749 4,106 3,458 Other regions 345 300 726 611 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of July 2, 2022 was $27.70 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 58% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years. Contract-related Balances Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: July 2, December 31, (In millions) 2022 2021 Current contract assets, net $ 1,147 $ 968 Noncurrent contract assets, net 10 9 Current contract liabilities 2,722 2,655 Noncurrent contract liabilities 1,237 1,238 In the three and six months ended July 2, 2022, the company recognized revenues of $0.71 billion and $1.99 billion, respectively, that were included in the contract liabilities balance at December 31, 2021. In the three and six months ended July 3, 2021, the company recognized revenues of $0.37 billion and $0.93 billion, respectively, that were included in the contract liabilities balance at December 31, 2020.

Business Segment and Geographic

Business Segment and Geographical Information	6 Months Ended
	Jul. 02, 2022
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information Business Segment Information Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues Life Sciences Solutions $ 3,292 $ 3,557 $ 7,523 $ 7,760 Analytical Instruments 1,607 1,481 3,125 2,868 Specialty Diagnostics 1,101 1,235 2,583 2,850 Laboratory Products and Biopharma Services 5,537 3,583 10,979 7,180 Eliminations (567) (583) (1,422) (1,479) Consolidated revenues 10,970 9,273 22,788 19,179 Segment Income Life Sciences Solutions 1,327 1,718 3,503 3,997 Analytical Instruments 344 280 645 552 Specialty Diagnostics 243 245 596 673 Laboratory Products and Biopharma Services 691 446 1,311 977 Subtotal reportable segments 2,605 2,689 6,055 6,199 Cost of revenues adjustments (8) — (19) (8) Selling, general and administrative expenses adjustments 28 42 21 26 Restructuring and other costs (24) (119) (26) (133) Amortization of acquisition-related intangible assets (600) (449) (1,209) (872) Consolidated operating income 2,001 2,163 4,822 5,212 Interest income 36 11 54 23 Interest expense (148) (122) (284) (247) Other income/(expense) 28 (3) (135) (186) Income before income taxes $ 1,917 $ 2,049 $ 4,457 $ 4,802 Cost of revenues adjustments included in the above table consist of charges for the sale of inventories revalued at the date of acquisition. Selling, general and administrative expenses adjustments included in the above table consist of third-party transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration. Geographical Information Revenues by country based on customer location are as follows: Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues United States $ 5,846 $ 4,355 $ 11,943 $ 9,247 China 1,001 794 1,911 1,569 Other 4,123 4,124 8,934 8,363 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179

Income Taxes

Income Taxes	6 Months Ended
	Jul. 02, 2022
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 5. Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Six months ended July 2, July 3, (In millions) 2022 2021 Statutory federal income tax rate 21 % 21 % Provision for income taxes at statutory rate $ 936 $ 1,008 Increases (decreases) resulting from: Foreign rate differential (138) (73) Income tax credits (117) (173) Global intangible low-taxed income 46 50 Foreign-derived intangible income (71) (89) Excess tax benefits from stock options and restricted stock units (31) (47) Intra-entity transfers (18) (162) Valuation allowances (175) 29 Withholding taxes 33 28 State income taxes, net of federal tax 67 78 Other, net (33) (14) Provision for income taxes $ 499 $ 635 The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. Unrecognized Tax Benefits As of July 2, 2022 the company had $1.10 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2022 Balance at beginning of year $ 1,124 Additions for tax positions of current year 13 Closure of tax years (2) Settlements (32) Balance at end of period $ 1,103

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 02, 2022
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 6. Earnings per Share Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions except per share amounts) 2022 2021 2022 2021 Net income attributable to Thermo Fisher Scientific Inc. $ 1,664 $ 1,828 $ 3,879 $ 4,165 Basic weighted average shares 392 393 392 394 Plus effect of: stock options and restricted stock units 2 3 2 3 Diluted weighted average shares 394 396 394 397 Basic earnings per share $ 4.25 $ 4.65 $ 9.90 $ 10.58 Diluted earnings per share $ 4.22 $ 4.61 $ 9.83 $ 10.50 Antidilutive stock options excluded from diluted weighted average shares 2 1 2 1

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	6 Months Ended
	Jul. 02, 2022
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 7. Debt and Other Financing Arrangements Effective interest rate at July 2, July 2, December 31, (Dollars in millions) 2022 2022 2021 Commercial Paper $ — $ 2,522 Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 1,000 1,000 Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 500 500 0.797% 2-Year Senior Notes, Due 10/18/2023 1.04 % 1,350 1,350 Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.00 % 1,770 1,933 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.06 % 573 625 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.93 % 1,041 1,137 1.215% 3-Year Senior Notes, Due 10/18/2024 1.42 % 2,500 2,500 Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 500 500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.40 % 833 910 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 666 728 0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 0.15 % 573 625 3.65% 10-Year Senior Notes, Due 12/15/2025 — 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.52 % 729 796 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 521 568 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.96 % 625 682 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.76 % 833 910 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 625 682 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.07 % 729 796 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.88 % 1,822 1,990 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 937 1,023 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.54 % 625 682 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,562 1,706 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 729 796 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 937 1,023 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 Effective interest rate at July 2, July 2, December 31, (Dollars in millions) 2022 2022 2021 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.76 % 1,302 1,421 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,041 1,137 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.06 % 781 853 Other 74 76 Total borrowings at par value 30,328 34,971 Unamortized discount (107) (117) Unamortized debt issuance costs (161) (184) Total borrowings at carrying value 30,060 34,670 Finance lease liabilities 200 200 Less: Short-term obligations and current maturities 1,010 2,537 Long-term obligations $ 29,250 $ 32,333 SOFR - Secured Overnight Financing Rate EURIBOR - Euro Interbank Offered Rate The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs. See Note 10 for fair value information pertaining to the company’s long-term borrowings. Credit Facilities The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of July 2, 2022, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of July 2, 2022, there were no outstanding borrowings under these programs. Senior Notes Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at July 2, 2022. In the first quarter of 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the Floating Rate Senior Notes due 2023, the 0.00% Senior Notes due 2023, the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051 included in the table above (collectively, the “Euronotes”) in registered public offerings. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jul. 02, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 8. Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At July 2, 2022, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2021 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2021 financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At July 2, 2022, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2021 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jul. 02, 2022
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 9. Comprehensive Income Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2021 $ (2,065) $ (35) $ (229) $ (2,329) Other comprehensive items before reclassifications (416) — 9 (407) Amounts reclassified from accumulated other comprehensive items 7 1 4 12 Net other comprehensive items (409) 1 13 (395) Balance at July 2, 2022 $ (2,474) $ (34) $ (216) $ (2,724)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	6 Months Ended
	Jul. 02, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 10. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: July 2, Quoted Significant Significant (In millions) 2022 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 173 $ 173 $ — $ — Investments 64 64 — — Warrants 13 — 13 — Insurance contracts 153 — 153 — Derivative contracts 103 — 103 — Total assets $ 506 $ 237 $ 269 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 216 — — 216 Total liabilities $ 217 $ — $ 1 $ 216 December 31, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 2,210 $ 2,210 $ — $ — Investments 298 298 — — Warrants 15 — 15 — Insurance contracts 181 — 181 — Derivative contracts 36 — 36 — Total assets $ 2,740 $ 2,508 $ 232 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 317 — — 317 Total liabilities $ 318 $ — $ 1 $ 317 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. In the three and six months ended July 2, 2022, the company recorded $17 million and $(122) million, respectively, of net gains (losses) on investments which are included in other income/(expense) in the accompanying statement of income. In the three and six months ended July 3, 2021, the company recorded $1 million and $2 million, respectively, of net losses on investments which are included in other income/(expense) in the accompanying statement of income. The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Contingent consideration Beginning balance $ 261 $ 227 $ 317 $ 70 Acquisitions (including assumed balances) — 17 (18) 179 Payments (2) (35) (32) (42) Changes in fair value included in earnings (43) (60) (51) (58) Ending balance $ 216 $ 149 $ 216 $ 149 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. July 2, December 31, (In millions) 2022 2021 Notional amount Cross-currency interest rate swaps - designated as net investment hedges $ 900 $ 900 Currency exchange contracts 1,571 2,149 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. Fair value – assets Fair value – liabilities July 2, December 31, July 2, December 31, (In millions) 2022 2021 2022 2021 Derivatives designated as hedging instruments Cross-currency interest rate swaps (a) $ 98 $ 25 $ — $ — Derivatives not designated as hedging instruments Currency exchange contracts (b) 5 11 1 1 Total derivatives $ 103 $ 36 $ 1 $ 1 (a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. Gain (loss) recognized Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Fair value hedging relationships Interest rate swaps Hedged long-term obligations - included in other income/(expense) $ — $ — $ — $ 25 Derivatives designated as hedging instruments - included in other income/(expense) — — — (3) Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other income/(expense) (1) (2) (2) (19) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive items 671 (90) 1,033 376 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 51 (6) 74 32 Included in other income/(expense) 4 2 6 4 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 21 (11) 12 1 Included in other income/(expense) 13 (28) 12 155 Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2021 included in the company’s Annual Report on Form 10-K for additional information on the company’s risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt instruments are as follows: July 2, 2022 December 31, 2021 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 29,986 $ 27,265 $ 32,072 $ 33,449 Commercial paper — — 2,522 2,522 Other 74 74 76 76 $ 30,060 $ 27,339 $ 34,670 $ 36,047 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jul. 02, 2022
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 11. Supplemental Cash Flow Information Six months ended July 2, July 3, (In millions) 2022 2021 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment $ 234 $ 225 Fair value of acquisition contingent consideration — 179 Declared but unpaid dividends 119 104 Issuance of stock upon vesting of restricted stock units 107 97 Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: July 2, December 31, (In millions) 2022 2021 Cash and cash equivalents $ 1,888 $ 4,477 Restricted cash included in other current assets 16 13 Restricted cash included in other assets 1 1 Cash, cash equivalents and restricted cash $ 1,905 $ 4,491 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs

Restructuring and Other Costs	6 Months Ended
	Jul. 02, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 12. Restructuring and Other Costs In the first six months of 2022, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company’s workforce. As of August 5, 2022, the company has identified restructuring actions that will result in additional charges of approximately $20 million, primarily in 2022, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. Restructuring and other costs by segment are as follows: Three months ended Six months ended July 2, July 2, (In millions) 2022 2022 Life Sciences Solutions $ 5 $ 6 Analytical Instruments 2 4 Specialty Diagnostics 2 3 Laboratory Products and Biopharma Services 15 13 $ 24 $ 26 The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2021 $ 17 Net restructuring charges incurred in 2022 (b) 22 Payments (24) Balance at July 2, 2022 $ 15 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Excludes $4 million of net non-cash charges. The company expects to pay accrued restructuring costs primarily through 2022.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 02, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company will adopt this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of transactions of this nature entered into by the company.
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Acquisitions (Policies)

Acquisitions (Policies)	6 Months Ended
	Jul. 02, 2022
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jul. 02, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories [Table Text Block]	Inventories The components of inventories are as follows: July 2, December 31, (In millions) 2022 2021 Raw materials $ 2,335 $ 1,922 Work in process 699 676 Finished goods 2,634 2,453 Inventories $ 5,668 $ 5,051

Revenue and Contract-related _2

Revenue and Contract-related Balances (Tables)	6 Months Ended
	Jul. 02, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenues Revenues by type are as follows: Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues Consumables $ 4,993 $ 5,372 $ 11,103 $ 11,336 Instruments 2,010 1,842 3,917 3,734 Services 3,967 2,059 7,768 4,109 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179 Revenues by geographic region based on customer location are as follows: Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues North America $ 6,032 $ 4,529 $ 12,355 $ 9,630 Europe 2,551 2,695 5,601 5,480 Asia-Pacific 2,042 1,749 4,106 3,458 Other regions 345 300 726 611 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179
Contract with Customer, Asset and Liability [Table Text Block]	Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: July 2, December 31, (In millions) 2022 2021 Current contract assets, net $ 1,147 $ 968 Noncurrent contract assets, net 10 9 Current contract liabilities 2,722 2,655 Noncurrent contract liabilities 1,237 1,238

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	6 Months Ended
	Jul. 02, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues Life Sciences Solutions $ 3,292 $ 3,557 $ 7,523 $ 7,760 Analytical Instruments 1,607 1,481 3,125 2,868 Specialty Diagnostics 1,101 1,235 2,583 2,850 Laboratory Products and Biopharma Services 5,537 3,583 10,979 7,180 Eliminations (567) (583) (1,422) (1,479) Consolidated revenues 10,970 9,273 22,788 19,179 Segment Income Life Sciences Solutions 1,327 1,718 3,503 3,997 Analytical Instruments 344 280 645 552 Specialty Diagnostics 243 245 596 673 Laboratory Products and Biopharma Services 691 446 1,311 977 Subtotal reportable segments 2,605 2,689 6,055 6,199 Cost of revenues adjustments (8) — (19) (8) Selling, general and administrative expenses adjustments 28 42 21 26 Restructuring and other costs (24) (119) (26) (133) Amortization of acquisition-related intangible assets (600) (449) (1,209) (872) Consolidated operating income 2,001 2,163 4,822 5,212 Interest income 36 11 54 23 Interest expense (148) (122) (284) (247) Other income/(expense) 28 (3) (135) (186) Income before income taxes $ 1,917 $ 2,049 $ 4,457 $ 4,802
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues Life Sciences Solutions $ 3,292 $ 3,557 $ 7,523 $ 7,760 Analytical Instruments 1,607 1,481 3,125 2,868 Specialty Diagnostics 1,101 1,235 2,583 2,850 Laboratory Products and Biopharma Services 5,537 3,583 10,979 7,180 Eliminations (567) (583) (1,422) (1,479) Consolidated revenues 10,970 9,273 22,788 19,179 Segment Income Life Sciences Solutions 1,327 1,718 3,503 3,997 Analytical Instruments 344 280 645 552 Specialty Diagnostics 243 245 596 673 Laboratory Products and Biopharma Services 691 446 1,311 977 Subtotal reportable segments 2,605 2,689 6,055 6,199 Cost of revenues adjustments (8) — (19) (8) Selling, general and administrative expenses adjustments 28 42 21 26 Restructuring and other costs (24) (119) (26) (133) Amortization of acquisition-related intangible assets (600) (449) (1,209) (872) Consolidated operating income 2,001 2,163 4,822 5,212 Interest income 36 11 54 23 Interest expense (148) (122) (284) (247) Other income/(expense) 28 (3) (135) (186) Income before income taxes $ 1,917 $ 2,049 $ 4,457 $ 4,802
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Revenues United States $ 5,846 $ 4,355 $ 11,943 $ 9,247 China 1,001 794 1,911 1,569 Other 4,123 4,124 8,934 8,363 Consolidated revenues $ 10,970 $ 9,273 $ 22,788 $ 19,179

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jul. 02, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Six months ended July 2, July 3, (In millions) 2022 2021 Statutory federal income tax rate 21 % 21 % Provision for income taxes at statutory rate $ 936 $ 1,008 Increases (decreases) resulting from: Foreign rate differential (138) (73) Income tax credits (117) (173) Global intangible low-taxed income 46 50 Foreign-derived intangible income (71) (89) Excess tax benefits from stock options and restricted stock units (31) (47) Intra-entity transfers (18) (162) Valuation allowances (175) 29 Withholding taxes 33 28 State income taxes, net of federal tax 67 78 Other, net (33) (14) Provision for income taxes $ 499 $ 635
Summary of Income Tax Contingencies [Table Text Block]	(In millions) 2022 Balance at beginning of year $ 1,124 Additions for tax positions of current year 13 Closure of tax years (2) Settlements (32) Balance at end of period $ 1,103

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Jul. 02, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions except per share amounts) 2022 2021 2022 2021 Net income attributable to Thermo Fisher Scientific Inc. $ 1,664 $ 1,828 $ 3,879 $ 4,165 Basic weighted average shares 392 393 392 394 Plus effect of: stock options and restricted stock units 2 3 2 3 Diluted weighted average shares 394 396 394 397 Basic earnings per share $ 4.25 $ 4.65 $ 9.90 $ 10.58 Diluted earnings per share $ 4.22 $ 4.61 $ 9.83 $ 10.50 Antidilutive stock options excluded from diluted weighted average shares 2 1 2 1

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	6 Months Ended
	Jul. 02, 2022
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective interest rate at July 2, July 2, December 31, (Dollars in millions) 2022 2022 2021 Commercial Paper $ — $ 2,522 Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 1,000 1,000 Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 500 500 0.797% 2-Year Senior Notes, Due 10/18/2023 1.04 % 1,350 1,350 Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.00 % 1,770 1,933 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 0.06 % 573 625 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.93 % 1,041 1,137 1.215% 3-Year Senior Notes, Due 10/18/2024 1.42 % 2,500 2,500 Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 500 500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.40 % 833 910 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 666 728 0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 0.15 % 573 625 3.65% 10-Year Senior Notes, Due 12/15/2025 — 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.52 % 729 796 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 521 568 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.96 % 625 682 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.76 % 833 910 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 625 682 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.07 % 729 796 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.88 % 1,822 1,990 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 937 1,023 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.54 % 625 682 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,562 1,706 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 729 796 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 937 1,023 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 Effective interest rate at July 2, July 2, December 31, (Dollars in millions) 2022 2022 2021 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.76 % 1,302 1,421 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,041 1,137 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.06 % 781 853 Other 74 76 Total borrowings at par value 30,328 34,971 Unamortized discount (107) (117) Unamortized debt issuance costs (161) (184) Total borrowings at carrying value 30,060 34,670 Finance lease liabilities 200 200 Less: Short-term obligations and current maturities 1,010 2,537 Long-term obligations $ 29,250 $ 32,333 SOFR - Secured Overnight Financing Rate EURIBOR - Euro Interbank Offered Rate

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jul. 02, 2022
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2021 $ (2,065) $ (35) $ (229) $ (2,329) Other comprehensive items before reclassifications (416) — 9 (407) Amounts reclassified from accumulated other comprehensive items 7 1 4 12 Net other comprehensive items (409) 1 13 (395) Balance at July 2, 2022 $ (2,474) $ (34) $ (216) $ (2,724)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jul. 02, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	July 2, Quoted Significant Significant (In millions) 2022 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 173 $ 173 $ — $ — Investments 64 64 — — Warrants 13 — 13 — Insurance contracts 153 — 153 — Derivative contracts 103 — 103 — Total assets $ 506 $ 237 $ 269 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 216 — — 216 Total liabilities $ 217 $ — $ 1 $ 216 December 31, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 2,210 $ 2,210 $ — $ — Investments 298 298 — — Warrants 15 — 15 — Insurance contracts 181 — 181 — Derivative contracts 36 — 36 — Total assets $ 2,740 $ 2,508 $ 232 $ — Liabilities Derivative contracts $ 1 $ — $ 1 $ — Contingent consideration 317 — — 317 Total liabilities $ 318 $ — $ 1 $ 317
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Contingent consideration Beginning balance $ 261 $ 227 $ 317 $ 70 Acquisitions (including assumed balances) — 17 (18) 179 Payments (2) (35) (32) (42) Changes in fair value included in earnings (43) (60) (51) (58) Ending balance $ 216 $ 149 $ 216 $ 149
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. July 2, December 31, (In millions) 2022 2021 Notional amount Cross-currency interest rate swaps - designated as net investment hedges $ 900 $ 900 Currency exchange contracts 1,571 2,149
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair value – assets Fair value – liabilities July 2, December 31, July 2, December 31, (In millions) 2022 2021 2022 2021 Derivatives designated as hedging instruments Cross-currency interest rate swaps (a) $ 98 $ 25 $ — $ — Derivatives not designated as hedging instruments Currency exchange contracts (b) 5 11 1 1 Total derivatives $ 103 $ 36 $ 1 $ 1 (a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (loss) recognized Three months ended Six months ended July 2, July 3, July 2, July 3, (In millions) 2022 2021 2022 2021 Fair value hedging relationships Interest rate swaps Hedged long-term obligations - included in other income/(expense) $ — $ — $ — $ 25 Derivatives designated as hedging instruments - included in other income/(expense) — — — (3) Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other income/(expense) (1) (2) (2) (19) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive items 671 (90) 1,033 376 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 51 (6) 74 32 Included in other income/(expense) 4 2 6 4 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 21 (11) 12 1 Included in other income/(expense) 13 (28) 12 155
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: July 2, 2022 December 31, 2021 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 29,986 $ 27,265 $ 32,072 $ 33,449 Commercial paper — — 2,522 2,522 Other 74 74 76 76 $ 30,060 $ 27,339 $ 34,670 $ 36,047 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: July 2, 2022 December 31, 2021 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 29,986 $ 27,265 $ 32,072 $ 33,449 Commercial paper — — 2,522 2,522 Other 74 74 76 76 $ 30,060 $ 27,339 $ 34,670 $ 36,047 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jul. 02, 2022
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Six months ended July 2, July 3, (In millions) 2022 2021 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment $ 234 $ 225 Fair value of acquisition contingent consideration — 179 Declared but unpaid dividends 119 104 Issuance of stock upon vesting of restricted stock units 107 97
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: July 2, December 31, (In millions) 2022 2021 Cash and cash equivalents $ 1,888 $ 4,477 Restricted cash included in other current assets 16 13 Restricted cash included in other assets 1 1 Cash, cash equivalents and restricted cash $ 1,905 $ 4,491

Restructuring and Other Costs (

Restructuring and Other Costs (Tables)	6 Months Ended
	Jul. 02, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	Restructuring and other costs by segment are as follows: Three months ended Six months ended July 2, July 2, (In millions) 2022 2022 Life Sciences Solutions $ 5 $ 6 Analytical Instruments 2 4 Specialty Diagnostics 2 3 Laboratory Products and Biopharma Services 15 13 $ 24 $ 26
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2021 $ 17 Net restructuring charges incurred in 2022 (b) 22 Payments (24) Balance at July 2, 2022 $ 15 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 02, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 2,335	$ 1,922
Work in process	699	676
Finished goods	2,634	2,453
Inventories	$ 5,668	$ 5,051

Purchase Price Adjustments (Det

Purchase Price Adjustments (Details) $ in Millions	6 Months Ended
	Jul. 02, 2022 USD ($)
Business Combination and Asset Acquisition [Abstract]
Goodwill, Purchase Accounting Adjustments	$ 95
Finite-Lived Intangible Assets, Purchase Accounting Adjustments	(43)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment Other Liabilities	22
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets	34
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Contract Liabilities	29
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Contingent Consideration	(18)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Method Investments	$ (23)

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 10,970	$ 9,273	$ 22,788	$ 19,179
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	6,032	4,529	12,355	9,630
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,551	2,695	5,601	5,480
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,042	1,749	4,106	3,458
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	345	300	726	611
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	4,993	5,372	11,103	11,336
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,010	1,842	3,917	3,734
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 3,967	$ 2,059	$ 7,768	$ 4,109

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Jul. 02, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 27,700
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-02
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	58%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021	Dec. 31, 2021
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Current contract assets, net	$ 1,147		$ 1,147		$ 968
Noncurrent contract assets, net	10		10		9
Current contract liabilities	2,722		2,722		2,655
Noncurrent contract liabilities	1,237		1,237		$ 1,238
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 710	$ 370	$ 1,990	$ 930

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Segment Reporting Information [Line Items]
Revenues	$ 10,970	$ 9,273	$ 22,788	$ 19,179
Operating Income	2,001	2,163	4,822	5,212
Restructuring and other costs	(24)	(119)	(26)	(133)
Amortization of acquisition-related intangible assets			(1,209)	(872)
Interest income	36	11	54	23
Interest expense	(148)	(122)	(284)	(247)
Other income/(expense)	28	(3)	(135)	(186)
Income before income taxes	1,917	2,049	4,457	4,802
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs	(5)		(6)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs	(2)		(4)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs	(2)		(3)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs	(15)		(13)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	2,605	2,689	6,055	6,199
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	3,292	3,557	7,523	7,760
Operating Income	1,327	1,718	3,503	3,997
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues	1,607	1,481	3,125	2,868
Operating Income	344	280	645	552
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	1,101	1,235	2,583	2,850
Operating Income	243	245	596	673
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues	5,537	3,583	10,979	7,180
Operating Income	691	446	1,311	977
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues	(567)	(583)	(1,422)	(1,479)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues adjustments	(8)	0	(19)	(8)
Selling, general and administrative expenses adjustments	28	42	21	26
Restructuring and other costs	(24)	(119)	(26)	(133)
Amortization of acquisition-related intangible assets	$ (600)	$ (449)	$ (1,209)	$ (872)

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 10,970	$ 9,273	$ 22,788	$ 19,179
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	5,846	4,355	11,943	9,247
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,001	794	1,911	1,569
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,123	$ 4,124	$ 8,934	$ 8,363

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax rate			21%	21%
Provision for income taxes at statutory rate			$ 936	$ 1,008
Foreign rate differential			(138)	(73)
Income tax credits			(117)	(173)
Global intangible low-taxed income			46	50
Foreign-derived intangible income			(71)	(89)
Excess tax benefits from stock options and restricted stock units			(31)	(47)
Intra-entity transfers			(18)	(162)
Valuation allowances			(175)	29
Withholding taxes			33	28
State income taxes, net of federal tax			67	78
Other, net			(33)	(14)
Provision for income taxes	$ 198	$ 219	$ 499	$ 635

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	6 Months Ended
	Jul. 02, 2022 USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 1,124
Additions for tax positions of current year	13
Closure of tax years	(2)
Settlements	(32)
Balance at end of period	$ 1,103

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Earnings Per Share [Abstract]
Net income	$ 1,664	$ 1,828	$ 3,879	$ 4,165
Basic Weighted Average Shares	392	393	392	394
Effect of Stock Options and Restricted Units	2	3	2	3
Diluted Weighted Average Shares	394	396	394	397
Basic Earnings Per Share (in dollars per share)	$ 4.25	$ 4.65	$ 9.90	$ 10.58
Diluted Earnings Per Share (in dollars per share)	$ 4.22	$ 4.61	$ 9.83	$ 10.50
Antidilutive stock options excluded from diluted weighted average shares	2	1	2	1

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Apr. 02, 2022	Jul. 02, 2022	Jul. 03, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Total borrowings at par value		$ 30,328		$ 34,971
Unamortized discount		(107)		(117)
Unamortized debt issuance costs		(161)		(184)
Total borrowings at carrying value		30,060		34,670
Finance lease liabilities		200		200
Less: Short-term obligations and current maturities		1,010		2,537
Long-term obligations		29,250		32,333
Losses on Extinguishment of Debt	$ 26	26	$ 197
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Total borrowings at par value				2,522
Total borrowings at carrying value				2,522
Senior Notes [Member]
Debt Instrument [Line Items]
Total borrowings at carrying value		$ 29,986		32,072
Debt Instrument, Call Feature		Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest.
Senior Notes [Member] | Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.35%
Debt Instrument, Term		1 year 6 months
Debt Instrument, Maturity Date		Apr. 18, 2023
Total borrowings at par value		$ 1,000		1,000
Senior Notes [Member] | Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.39%
Debt Instrument, Term		2 years
Debt Instrument, Maturity Date		Oct. 18, 2023
Total borrowings at par value		$ 500		500
Senior Notes [Member] | 0.797% 2-Year Senior Notes, Due 10/18/2023
Debt Instrument [Line Items]
Stated Interest Rate		0.797%
Debt Instrument, Term		2 years
Debt Instrument, Maturity Date		Oct. 18, 2023
Effective Interest Rate		1.04%
Total borrowings at par value		$ 1,350		1,350
Senior Notes [Member] | Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.20%
Debt Instrument, Term		2 years
Debt Instrument, Maturity Date		Nov. 18, 2023
Effective Interest Rate		0%
Total borrowings at par value		$ 1,770		1,933
Senior Notes [Member] | 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0%
Debt Instrument, Term		2 years
Debt Instrument, Maturity Date		Nov. 18, 2023
Effective Interest Rate		0.06%
Total borrowings at par value		$ 573		625
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.75%
Debt Instrument, Term		8 years
Debt Instrument, Maturity Date		Sep. 12, 2024
Effective Interest Rate		0.93%
Total borrowings at par value		$ 1,041		1,137
Senior Notes [Member] | 1.215% 3-Year Senior Notes, Due 10/18/2024
Debt Instrument [Line Items]
Stated Interest Rate		1.215%
Debt Instrument, Term		3 years
Debt Instrument, Maturity Date		Oct. 18, 2024
Effective Interest Rate		1.42%
Total borrowings at par value		$ 2,500		2,500
Senior Notes [Member] | Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.53%
Debt Instrument, Term		3 years
Debt Instrument, Maturity Date		Oct. 18, 2024
Total borrowings at par value		$ 500		500
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.125%
Debt Instrument, Term		5 years 6 months
Debt Instrument, Maturity Date		Mar. 01, 2025
Effective Interest Rate		0.40%
Total borrowings at par value		$ 833		910
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Apr. 15, 2025
Effective Interest Rate		2.09%
Total borrowings at par value		$ 666		728
Senior Notes [Member] | 0.000% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0%
Debt Instrument, Term		4 years
Debt Instrument, Maturity Date		Nov. 18, 2025
Effective Interest Rate		0.15%
Total borrowings at par value		$ 573		625
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025
Debt Instrument [Line Items]
Stated Interest Rate		3.65%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Dec. 15, 2025
Total borrowings at par value				350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.40%
Debt Instrument, Term		8 years 6 months
Debt Instrument, Maturity Date		Jan. 23, 2026
Effective Interest Rate		1.52%
Total borrowings at par value		$ 729		796
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.45%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Mar. 16, 2027
Effective Interest Rate		1.65%
Total borrowings at par value		$ 521		568
Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.75%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Apr. 15, 2027
Effective Interest Rate		1.96%
Total borrowings at par value		$ 625		682
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.50%
Debt Instrument, Term		8 years 6 months
Debt Instrument, Maturity Date		Mar. 01, 2028
Effective Interest Rate		0.76%
Total borrowings at par value		$ 833		910
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.375%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Sep. 12, 2028
Effective Interest Rate		1.46%
Total borrowings at par value		$ 625		682
Senior Notes [Member] | 1.750% 7-Year Senior Notes, Due 10/15/2028
Debt Instrument [Line Items]
Stated Interest Rate		1.75%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Oct. 15, 2028
Effective Interest Rate		1.89%
Total borrowings at par value		$ 700		700
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.95%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Jul. 24, 2029
Effective Interest Rate		2.07%
Total borrowings at par value		$ 729		796
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Stated Interest Rate		2.60%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Oct. 01, 2029
Effective Interest Rate		2.74%
Total borrowings at par value		$ 900		900
Senior Notes [Member] | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.80%
Debt Instrument, Term		9 years
Debt Instrument, Maturity Date		Oct. 18, 2030
Effective Interest Rate		0.88%
Total borrowings at par value		$ 1,822		1,990
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.875%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Oct. 01, 2031
Effective Interest Rate		1.13%
Total borrowings at par value		$ 937		1,023
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 10/15/2031
Debt Instrument [Line Items]
Stated Interest Rate		2%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Oct. 15, 2031
Effective Interest Rate		2.23%
Total borrowings at par value		$ 1,200		1,200
Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.375%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Apr. 15, 2032
Effective Interest Rate		2.54%
Total borrowings at par value		$ 625		682
Senior Notes [Member] | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.125%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Oct. 18, 2033
Effective Interest Rate		1.20%
Total borrowings at par value		$ 1,562		1,706
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.875%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Jul. 24, 2037
Effective Interest Rate		2.94%
Total borrowings at par value		$ 729		796
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.50%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Oct. 01, 2039
Effective Interest Rate		1.73%
Total borrowings at par value		$ 937		1,023
Senior Notes [Member] | 2.80% 20-Year Senior Notes, Due 10/15/2041
Debt Instrument [Line Items]
Stated Interest Rate		2.80%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Oct. 15, 2041
Effective Interest Rate		2.90%
Total borrowings at par value		$ 1,200		1,200
Senior Notes [Member] | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.625%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Oct. 18, 2041
Effective Interest Rate		1.76%
Total borrowings at par value		$ 1,302		1,421
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Stated Interest Rate		5.30%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Feb. 01, 2044
Effective Interest Rate		5.37%
Total borrowings at par value		$ 400		400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Stated Interest Rate		4.10%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Aug. 15, 2047
Effective Interest Rate		4.23%
Total borrowings at par value		$ 750		750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.875%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Oct. 01, 2049
Effective Interest Rate		1.98%
Total borrowings at par value		$ 1,041		1,137
Senior Notes [Member] | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Oct. 18, 2051
Effective Interest Rate		2.06%
Total borrowings at par value		$ 781		853
Other Debt [Member]
Debt Instrument [Line Items]
Total borrowings at par value		74		76
Total borrowings at carrying value		$ 74		$ 76

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	6 Months Ended
	Jul. 02, 2022 USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity	$ 5,000,000,000
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3.5
Line of Credit Facility, Amount Outstanding	$ 0
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 41,018	$ 35,068	$ 40,855	$ 34,517
Total other comprehensive items	(382)	(68)	(395)	177
Balance	42,354	36,901	42,354	36,901
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(2,065)
Other comprehensive items before reclassifications			(416)
Amounts reclassified from accumulated other comprehensive items			7
Total other comprehensive items			(409)
Balance	(2,474)		(2,474)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(35)
Amounts reclassified from accumulated other comprehensive items			1
Total other comprehensive items			1
Balance	(34)		(34)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(229)
Other comprehensive items before reclassifications			9
Amounts reclassified from accumulated other comprehensive items			4
Total other comprehensive items			13
Balance	(216)		(216)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,343)	(2,562)	(2,329)	(2,807)
Other comprehensive items before reclassifications			(407)
Amounts reclassified from accumulated other comprehensive items			12
Total other comprehensive items	(381)	(68)	(395)	177
Balance	$ (2,724)	$ (2,630)	$ (2,724)	$ (2,630)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021	Dec. 31, 2021
Liabilities [Abstract]
Gain (Loss) on Investments	$ 17	$ (1)	$ (122)	$ (2)
Fair Value, Recurring [Member]
Assets [Abstract]
Cash equivalents	173		173		$ 2,210
Investments	64		64		298
Warrants	13		13		15
Insurance contracts	153		153		181
Derivative contracts	103		103		36
Total Assets	506		506		2,740
Liabilities [Abstract]
Derivative contracts	1		1		1
Contingent consideration	216		216		317
Total Liabilities	217		217		318
Fair Value, Recurring [Member] | Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	173		173		2,210
Investments	64		64		298
Total Assets	237		237		2,508
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	13		13		15
Insurance contracts	153		153		181
Derivative contracts	103		103		36
Total Assets	269		269		232
Liabilities [Abstract]
Derivative contracts	1		1		1
Total Liabilities	1		1		1
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	216		216		317
Total Liabilities	$ 216		$ 216		$ 317

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 261	$ 227	$ 317	$ 70
Acquisitions (including assumed balances)		17	(18)	179
Payments	(2)	(35)	(32)	(42)
Changes in fair value included in earnings	(43)	(60)	(51)	(58)
Ending balance	$ 216	$ 149	$ 216	$ 149
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]	Selling, general and administrative expenses	Selling, general and administrative expenses	Selling, general and administrative expenses	Selling, general and administrative expenses

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Jul. 02, 2022	Dec. 31, 2021
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 98	$ 25
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,571	2,149
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	5	11
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	1	1
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	103	36
Derivative Liabilities	$ 1	$ 1

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 21	$ (11)	$ 12	$ 1
Currency Exchange Contracts [Member] | Other Income (Expense) [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	13	(28)	12	155
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Hedged long-term obligations in Fair Value Hedge				25
Gain (Loss) on Derivative, Net				(3)
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Reclassified from AOCI	(1)	(2)	(2)	(19)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	671	(90)	1,033	376
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	51	(6)	74	32
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 4	$ 2	$ 6	$ 4

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Jul. 02, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ 27,339	$ 36,047
Long-term Debt	30,060	34,670
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	27,265	33,449
Long-term Debt	29,986	32,072
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure		2,522
Long-term Debt		2,522
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	74	76
Long-term Debt	$ 74	$ 76

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Dec. 31, 2021	Dec. 31, 2020
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	$ 234	$ 225
Fair value of acquisition contingent consideration		179
Declared but unpaid dividends	119	104
Issuance of stock upon vesting of restricted stock units	107	97
Cash and Cash Equivalents	1,888		$ 4,477
Restricted cash included in other current assets	16		13
Restricted cash included in other assets	1		1
Cash, cash equivalents and restricted cash	$ 1,905	$ 7,035	$ 4,491	$ 10,336
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	Other assets

Restructuring and Other Costs_2

Restructuring and Other Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 02, 2022	Jul. 03, 2021	Jul. 02, 2022	Jul. 03, 2021	Aug. 05, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated less than			0.50%
Restructuring and other costs	$ 24	$ 119	$ 26	$ 133
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	5		6
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	2		4
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	2		3
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 15		$ 13
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs					$ 20

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	6 Months Ended
	Jul. 02, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 17
Net restructuring charges incurred in 2022 (b)	22
Payments	(24)
Ending balance	15
Restructuring and Related Costs, Other Costs (Income)	$ 4
Restructuring Reserve, Expected Final Year of Payments	2022